Merck & Co Inc stated on Wednesday the U.S. authorities have agreed to purchase about 1.7 million publications of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if it is licensed in the country.
Molnupiravir is an experimental antiviral remedy Merck is creating with Ridgeback Biotherapeutics for the remedy of COVID-19 sufferers who are now not hospitalized.
The drug is presently being assessed in a late-stage trial for its possibility to limit the danger of hospitalization or death.
Merck stated it expects to file for the emergency use authorization of molnupiravir in the 2d half of 2021 at the earliest, pending favorable outcomes from the trial.
The drug is administered orally in tablet shape each and every 12 hours for 5 days and a remedy direction incorporates 10 doses in total.
Merck expects to have greater than 10 million publications of remedy handy by using the cease of this yr and stated it used to be in discussions with different international locations involved in enhancing buy agreements for molnupiravir.
Merck has decided to focal point on its pills for COVID-19 after two vaccines failed to generate preferred immune responses, prompting it to abandon the software in January.
Merck | Don’t forget to follow us on Twitter @njtimesofficial. To get latest updates
